Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Capital Raise

Surrozen Inc. Prices $60 Million Public Offering of Common Stock at $31.67 Per Share

Surrozen, Inc. has entered into a definitive underwriting agreement for a common stock offering expected to generate $60 million in gross proceeds. The transaction involves the sale of approximately 1.9 million shares to support corporate initiatives and clinical development.

Entrepreneur, start-up, man, planning. Stock photo illustrating Surrozen's capital raise story.
Surrozen, Inc./DE · Healthcare · Photo: StartupStockPhotos / Pixabay
Key numbers
Deal value$60M
Share of market cap10.0%

Key highlights

  • Offering of 1,894,540 shares of common stock at a fixed price of $31.67 per share
  • Expected gross proceeds of approximately $60 million before underwriting discounts
  • Underwriting syndicate led by Morgan Stanley, Guggenheim Securities, and Cantor Fitzgerald
  • Transaction scheduled to close on November 16, 2026, subject to customary conditions
  • Issuance conducted under an existing effective Form S-3 registration statement

What Is the Capital Raise?

Surrozen, Inc. has priced a public offering of 1,894,540 shares of common stock at $31.67 per share, representing a total gross value of approximately $60 million. This capital raise is being conducted through a syndicate of underwriters led by Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co. The pricing of $31.67 sits close to the recent market trading price of $31.61. The company expects the transaction to conclude by November 16, 2026, pending the fulfillment of standard closing conditions. The shares are being issued under a shelf registration statement previously filed with the SEC.

Strategic Rationale

The timing of this capital raise follows a period of significant stock price appreciation, with Surrozen shares gaining 33.09 percent over the last month and 30.67 percent over the last quarter. By accessing the equity markets during this period of increased valuation, the company strengthens its liquidity position without relying on debt instruments. This move signals management's intent to capitalize on favorable market sentiment to fund ongoing operations. The involvement of major investment banks like Morgan Stanley suggests institutional interest in the company's current pipeline development and clinical milestones within the biotechnology sector.

Surrozen, Inc./DE share price · last month
Line chart of Surrozen, Inc./DE's share price over the last month, from $23.84 on 19 Oct → $32.32 on 16 Nov; our story on 16 Nov at $31.61.

Up 2.2% since our story on 16 Nov: $31.61 when we broke it → $32.32 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$23.84
20 Oct$25.14
21 Oct$25.32
22 Oct$25.75
23 Oct$25.48
26 Oct$27.28
27 Oct$29.53
28 Oct$30.35
29 Oct$29.46
30 Oct$29.04
2 Nov$29.02
3 Nov$30.12
4 Nov$31.65
5 Nov$29.00
6 Nov$31.00
9 Nov$32.00
10 Nov$32.64
11 Nov$31.88
12 Nov$31.67
13 Nov$31.61
16 Nov$32.32

Business Overview

Surrozen is a clinical-stage biotechnology firm based in South San Francisco, California, specializing in the development of targeted antibodies. The company focuses on modulating the Wnt signaling pathway, a critical biological mechanism involved in tissue repair and regeneration. Its proprietary platforms, including YSNC and SWAP, are designed to create tissue-specific antibodies that can potentially treat a variety of diseases where tissue damage is a primary factor. By targeting specific receptors, Surrozen aims to stimulate the body’s natural repair processes in organs such as the liver, intestine, and lungs.

Financial and Industry Context

  • Surrozen reported annual revenue of $3.477 million, reflecting its status as a clinical-stage entity focused on R&D
  • The company maintains a market capitalization of approximately $602.5 million following recent momentum in the healthcare sector
  • Biotechnology funding trends in late 2026 show a continued reliance on follow-on offerings to sustain long-term clinical trials
  • Technical indicators show a Relative Strength Index of 59.5, placing the stock in a neutral momentum zone
  • The biotech industry remains sensitive to regulatory milestones, necessitating robust cash reserves for multi-year projects
Surrozen, Inc./DE · financial snapshot
Share price$31.61
Market cap$603M
Revenue (annual)$3M
1-month price change+33.09%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Surrozen, Inc. announcing a $60 million underwriting agreement for a public stock offering.

Read the filing ↗
All Surrozen, Inc./DE filings and newsView all →

Track Surrozen, Inc./DE live

Get the next Surrozen, Inc./DE SEC filing seconds after it lands.

More from Surrozen, Inc./DE

All →

More in Capital Raise

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.